13th Jan 2020 09:01
(Alliance News) - Hutchison China MediTech Ltd said Monday it has initiated a phase II study in China of surufatinib in combination with Tuoyi in patients with advanced solid tumors.
Surufatinib is an inhibitor being developed for the treatment on advanced non-pancreatic neuroendocrine tumours.
The company said this follows the recent completion of the phase I dose finding study and successful establishment of the phase II combination dosing regimen for surufatinib and Tuoyi.
This study is part of a global collaboration with Shanghai Junshi Biosciences Co Ltd to evaluate surufatinib, Chi-Med's oral angio-immuno kinase inhibitor, in combination with Tuoyi, Junshi's anti-programmed cell death protein 1 monoclonal antibody.
The cell death protein 1 monoclonal antibody was approved by China's National Medical Products Administration in December 2018, the company noted.
The study is designed to test the potential synergistic anti-tumor effects of the combination's ability to simultaneously target multiple cell types and signaling pathways in the tumor microenvironment, the company said.
Christian Hogg, chief executive officer of Chi-Med, said: "We are excited to move into phase II development on the surufatinib toripalimab combination and look forward to identifying patient groups that could benefit from this innovative treatment regimen."
Hutchison China MediTech shares were down 2.2% in London at 393.30 pence each on Monday.
By Loreta Juodagalvyte; [email protected]
Copyright 2020 Alliance News Limited. All Rights Reserved.
Related Shares:
Hutchmed